Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Recruiting now · Phase 2

Conditions studied: MSI-H/dMMR Solid Tumors

In brief

In this Phase 2, Single-Arm, Multi-Center, Open-Label Study, participants with previously treated locally advanced unresectable or metastatic solid tumors with mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) will be treated with anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317).

Key facts

Study ID

NCT03736889

Run by

BeiGene

People needed

200

Starts

2018-09-19

Expected to finish

2027-09-01

Last updated by the study team

2026-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Huizhou First Hospital — Huizhou, Guangdong, China (enrolling)
• Meizhou People Hospital — Meizhou, Guangdong, China (enrolling)
• Beijing Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)
• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China (enrolling)
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China (enrolling)
• Guangdong Provincial Peoples Hospital — Guangzhou, Guangdong, China
• Nanfang Hospital of Southern Medical University — Guangzhou, Guangdong, China
• The Sixth Affiliated Hospital, Sun Yat Sen University — Guangzhou, Guangdong, China
• The Peoples Hospital of Hechi — Hechi, Guangxi, China
• Affiliated Hospital of Hebei University — Baoding, Hebei, China
• Henan Cancer Hospital — Zhengzhou, Henan, China
• Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology — Wuhan, Hubei, China
• Hubei Cancer Hospital — Wuhan, Hubei, China
• Hunan Cancer Hospital — Changsha, Hunan, China
• Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School — Nanjing, Jiangsu, China
• Jiangsu Province Hospital — Nanjing, Jiangsu, China
• Jilin Cancer Hospital — Changchun, Jilin, China
• The General Hospital of Shenyang Military — Shenyang, Liaoning, China
• Yidu Central Hospital of Weifang — Weifang, Shandong, China
• Fudan University Shanghai Cancer Center — Shanghai, Shanghai Municipality, China
• Affiliated Zhongshan Hospital of Fudan University — Shanghai, Shanghai Municipality, China
• The First Peoples Hospital of Yibin — Yibin, Sichuan, China
• The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, Zhejiang, China
• Zhejiang University College of Medicine Second Affiliated Hospital — Hangzhou, Zhejiang, China
• Anhui Provincial Hospital — Hefei, Anhui, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.